3-(Tert-butylamino)pyrrolidine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(Tert-butylamino)pyrrolidine-1-carboxylic acid
• 化学式: C₉H₁₈N₂O₂
• 分子量: 186.25
• InChiKey: BYTVHWGCXFUVSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  52.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Triazolopyridine Compounds
  申请人：CHEN Chao

  公开号：US20130245002A1

  公开（公告）日：2013-09-19

  The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

  本发明涉及公式(I)化合物及其盐：其中取代基如说明书中所定义；用于治疗人体或动物体的公式(I)化合物，特别是针对c-Met酪氨酸激酶介导的疾病或状况；使用公式(I)化合物来制造用于治疗这类疾病的药物；包含公式(I)化合物的药物组合物，可选地与联合用药伴侣一起存在，以及制备公式(I)化合物的方法。
• [EN] METHYLPYRROLOPYRIMIDINECARBOXAMIDES<br/>[FR] MÉTHYLPYRROLOPYRIMIDINE-CARBOXAMIDES
  申请人：NYCOMED GMBH

  公开号：WO2011023693A1

  公开（公告）日：2011-03-03

  The compounds of formula (I) wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, and the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

  式（I）中的化合物，其中R1、R2、R21、R22、R23、R24、Y和R3的含义如描述中所述，其盐以及这些化合物和其盐的立体异构体是有效的第5型磷酸二酯酶抑制剂。
• METHYLPYRROLOPYRIMIDINECARBOXAMIDES
  申请人：Stadlwieser Josef

  公开号：US20120149721A1

  公开（公告）日：2012-06-14

  The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

  式（I）中的化合物，其中R1、R2、R21、R22、R23、R24、Y和R3的含义如描述中所示，其盐，化合物的立体异构体及其盐是有效的磷酸二酯酶5型抑制剂。
• CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
  申请人：LAMPE John W.

  公开号：US20130012543A1

  公开（公告）日：2013-01-10

  The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions.

  本发明涉及合成的细胞骨架活性化合物，其为rho相关蛋白激酶的抑制剂。本发明还涉及包含这种化合物和药物可接受的载体的制药组合物。此外，本发明还涉及预防或治疗与细胞骨架重组相关的疾病或状况的方法。在本发明的一个实施例中，该方法治疗增加的眼内压，如原发性开角型青光眼。该方法包括向受试者施用公式I或公式II的细胞骨架活性化合物的治疗有效量，其中该量有效地影响肌动蛋白相互作用，例如通过导致细胞松弛和细胞-基质粘附的改变。
• TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS
  申请人：NISSAN CHEMICAL INDUSTRIES, LTD.

  公开号：US20160102102A1

  公开（公告）日：2016-04-14

  This disclosure relates to novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities. A tricyclic heterocyclic compound represented by the formula (I b ), wherein the rings A b and B b , X b , Y b , R 1b , R 2b , R 3b , L 1b , L 2b , L 3b and n b are as defined in the specification.

  本披露涉及具有JAK抑制活性的新型三环嘧啶化合物和三环吡啶化合物。其中，由式(Ib)表示的三环杂环化合物，其中环Ab和Bb，Xb，Yb，R1b，R2b，R3b，L1b，L2b，L3b和nb的定义在说明书中。